[9] Lomize A, Lomize M, Pogozheva I. Orientations of proteins in membranes. http://opm.phar.umich.edu/protein.php?pdbid=1zmp, http://opm.phar.umich.edu/protein.php?pdbid=1zmq, http://opm.phar.umich.edu/protein.php?pdbid=1fd3 [Zugri am 17.05.2009] [10] Lehrer RI, Ganz T. Defensins: endogenous antibiotic peptides from human leukocytes. Ciba Found Symp 1992, 171:276-290. [11] Porter EM, van Dam E, Valore EV, Ganz T. Broad-spectrum antimicrobial activity of human intestinal defensin 5. Infect Immun 1997, 65(6):2396-2401. [12] Ganz T. Antimicrobial peptides of innate immunity. Nat Rev Immunol 2003, 3(9):710-720. [13] Cunlie RN, Rose FR, Keyte J, Abberley L, Chan WC, Mahida YR. Human defensin 5 is stored in precursors form in normal Paneth cells and is expressed by some villous epithelial cells and by metaplastic Paneth cells in the colon in inammatory bowel disease. Gut 2001, 48(2):176-185. [14] Eckmann L. Innate immunity and mucosal bacterial interactions in the intestine. Gastroenterology 2004, 20(2):82-88. [15] Bevins CL. Events at the host-microbial interface of the gastrointestinal tract. V. Paneth cell alpha-defensins in intestinal host defense. Am J Physiol Gastrointest Liver Physiol 2005, 289(2):G173-G176. [16] Ghosh D, Porter E, Shen B et al. Paneth cell trypsin is the processing enzyme for human defensin-5. Nat Immunol 2002, 3(6):583-590. [17] Ayabe T, Satchell DP, Wilson CL, Parks WC, Selsted ME, Ouellette AJ. Secretion of microbicidal alpha-defensins by intestinal Paneth cells in response to bacteria. Nat Immunol 2000, 1(2):113-118. [18] Oppenheim JJ, Biragyn A, Kwak LW, Yang D. Roles of antimicrobial peptides such as defensins in innate and adaptive immunity. Ann Rheum Dis 2003, 62(SupplII):ii17-ii21.
[19] Rumio C, Besusso D, Palazzo M et al. Degranulation of paneth cells via toll-like receptor 9. Am J Pathol 2004, 165(2):373-381. [20] Wilson CL, Ouellette AJ, Satchell DP et al. Regulation of intestinal -defensin activation by the metalloproteinase matrilysin in innate host defense. Science 1999, 286(5437):113-117. [21] Salzman NH, Ghosh D, Huttner KM, Paterson Y, Bevins CL. Protection against enteric salmonellosis in transgenic mice expressing a human intestinal defensin. Nature 2003, 422(6931):522-526. [22] Salzman NH, Chou MM, de Jong H, Liu L, Porter EM, Paterson Y. Enteric salmonella infection inhibits paneth cell antimicrobial peptide expression. Infect Immun 2003, 71(3):1109-1115. [23] Giesemann T, Guttenberg G, Aktories K. Human -defensins inhibit Clostridium dicile Toxin B. Gastroenterology 2008, 134(7):2049-2058. [24] Chertov O, Michiel DF, Xu L et al. Identication of defensin-1, defensin-2, and CAP37/azurocidin as T-cell chemoattractant proteins released from interleukin8-stimulated neutrophils. J Biol Chem 1996, 271(6):2935-2940. [25] Yang D, Chen Q, Chertov O, Oppenheim JJ. Human neutrophil defensins selectively chemoattract naive T and immature dendritic cells. J Leukoc Biol 2000, 68(1):9-14. [26] Furci L, Sironi F, Tolazzi M, Vassena L, Lusso P. -defensins block the early steps of HIV-1 infection: interference with the binding of gp120 to CD4. Blood 2007, 109(7):2928-2935. [27] Grigat J, Soruri A, Forssmann U, Riggert J, Zwirner J. Chemoattraction of macrophages, T lymphocytes, and mast cells is evolutionarily conserved within the human alpha-defensin family. J Immunol 2007, 179(6):3958-3965. [28] ONeil DA, Porter EM, Elewaut D et al. Expression and regulation of the human beta-defensins hBD-1 and hBD-2 in intestinal epithelium. J Immunol 1999, 163(12):6718-6724.

[29] Wehkamp J, Harder J, Wehkamp K et al. NF-B- and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel eect of a probiotic bacterium. Infect Immun 2004, 72(10):57505758. [30] Voss E, Wehkamp J, Wehkamp K, Stange EF, Schrder JM, Harder J. o NOD2/CARD15 mediates induction of the antimicrobial peptide -defensin2. J Biol Chem 2006, 281(4):2005-2011. [31] Lala S, Ogura Y, Osborne C et al. Crohns disease and the NOD2 gene: a role for Paneth cells. Gastroenterology 2003, 125(1):4757. [32] Ogura Y, Inohara N, Benito A, Chen FF, Yamaoka S, Nunez G. Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NFB. J Biol Chem 2001, 276(7):4812-4818. [33] Vora P, Youdim A, Thomas LS et al. -defensin-2 expression is regulated by TLR signaling in epithelial cells. J Immunol 2004, 173(9):5398-5405. [34] Tsutsumi-Ishii Y, Nagaoka I. NF-B-mediated transcriptional regulation of human -defensin-2 gene following lipopolysaccharide stimulation. J Leukoc Biol 2002, 71(1):154-162. [35] Cario E: Bacterial interactions with cells of the intestinal mucosa. Toll-like receptors and NOD2. Gut 2005, 54(8):1182-1193. [36] Fellermann K, Wehkamp J, Herrlinger KR, Stange EF. Crohns disease: a defensin deciency syndrome? Eur J Gastroenterol Hepatol 2003, 15(6):627-634. [37] Rogler G. Update in inammatory bowel disease pathogenesis. Gastroenterology 2004, 20:311-317. [38] Yang D, Chertov O, Bykovskaia SN et al. -Defensins: Linking innate and adaptive immunity through dendritic and T cell CCR6. Science 1999, 286(5439):525528. [39] Biragyn A, Runi PA, Leifer CA et al. Toll-like receptor 4dependent activation of dendritic cells by -defensin 2. Science 2002, 298(5595):1025-1029.
[40] Homann JC (Hrsg.), Kroesen AJ (Hrsg.), Klump B (Hrsg.). Chronisch entzndliche Darmerkrankungen. Georg Thieme Verlag Stuttgart, 2004, 1. Aufu lage. [41] Timmer A, Breuer-Katschinski B, Goebell H. Time trends in the incidence and disease location of Crohns disease 1980-1995: a prospective analysis in an urban population in Germany. Inamm Bowel Dis 1999, 5(2):79-84. [42] Cario E, Gerken G, Podolsky DK. For whom the bell tolls! Innate defense mechanisms and survival strategies of the intestinal epithelium against lumenal pathogens. Z Gastroenterol 2002, 40(12):983-990. [43] Barrett JC, Hansoul S, Nicolae DL et al. Genome-wide association denes more than 30 distinct susceptibility loci for Crohns disease. Nat Genet 2008, 40(8):955-962. [44] Ogura Y, Bonen DK, Inohara N et al. A frameshift mutation in NOD2 associated with susceptibility to Crohns disease. Nature 2001, 411(6837):603-606. [45] Ogura Y, Lala S, Xin W et al. Expression of NOD2 in Paneth cells: a possible link to Crohns ileitis. Gut 2003, 52(11):1591-1597. [46] Cobrin GM, Abreu MT. Defects in mucosal immunity leading to Crohns disease. Immunol Rev 2005, 206:277-295. [47] Subramanian S, Campbell BJ, Rhodes JM. Bacteria in the pathogenesis of inammatory bowel disease. Curr Opin Infect Dis 2006, 19(5):475484. [48] Tiede I, Fritz G, Strand S et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003, 111(8):1133-1145. [49] Mankertz J, Schulzke JD. Altered permeability in inammatory bowel disease: pathophysiology and clinical implications. Curr Opin Gastroenterol 2007, 23(4):379-383.

[50] Darfeuille-Michaud A, Neut C, Barnich N et al. Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohns disease. Gastroenterology 1998, 115(6):1405-1413. [51] Darfeuille-Michaud A, Boudeau J, Bulois P et al. High prevalence of adherentinvasive Escherichia coli associated with ileal mucosa in Crohns disease. Gastroenterology 2004, 127(2):412-421. [52] Swidsinski A, Ladho A, Pernthaler A. Mucosal ora in inammatory bowel disease. Gastroenterology 2002, 122(1):44-54. [53] Lawrance IC, Fiocchi C, Chakravarti S. Ulcerative colitis and Crohns disease: distinctive gene expression proles and novel susceptibility candidate genes. Hum Mol Genet 2001, 10(5):445-56. [54] Pag`s F, Lazar V, Berger A et al. Analysis of interleukin-18, interleukin-1 cone verting enzyme (ICE) and interleukin-18-related cytokines in Crohns disease lesions. Eur Cytokine Netw 2001, 12(1):97-104. [55] Autschbach F, Giese T, Gassler N et al. Cytokine/chemokine messenger-RNA expression proles in ulcerative colitis and Crohns disease. Virchows Arch 2002, 441(5):500-513. [56] Rosenstiel P, Fantini M, Brutigam K et al. TNF- and IFN- regulate the a expression of the NOD2 (CARD15) gene in human intestinal epithelial cells. Gastroenterology 2003, 124(4):10011009. [57] Hausmann M, Kiessling S, Mestermann S et al. Toll-like receptors 2 and 4 are up-regulated during intestinal inammation. Gastroenterology 2002, 122(7):19872000. [58] Rogler G, Brand K, Vogl D et al. Nuclear factor kappaB is activated in macrophages and epithelial cells of inamed intestinal mucosa. Gastroenterology 1998, 115(2):357-369.
[59] Homann JC, Prei JC, Autschbach F et al. S3 Leitlinie Diagnostik und Thera pie des Morbus Crohn. Ergebnisse einer evidenzbasierten Konsensuskonferenz der Deutschen Gesellschaft fr Verdauungs- und Stowechselkrankheiten zuu sammen mit dem Kompetenznetz Chronisch entzndliche Darmerkrankungen. u Z Gastroenterol 2008, 46(9):1094-1146. [60] Wehling M (Hrsg.). Klinische Pharmakologie. Georg Thieme Verlag Stuttgart, 2005, 1. Auage. [61] Visekruna A, Joeris T, Seidel D et al. Proteasome-mediated degradation of IB and processing of p105 in Crohns disease and ulceratice colitis. J Clin Invest 2006, 116(12):3195-3203. [62] Brosius F. SPSS 12. Mitp-Verlag Bonn, 2004, 1. Auage. [63] Podolsky DK. Inammatory bowel disease. N Engl J Med 2002, 347(6):417-429. [64] Mller CA, Autenrieth IB, Peschel A. Innate defenses of the intestinal epithelial u barrier. Cell Mol Life Sci 2005, 62(12):1297-1307. [65] Schmid M, Fellermann K, Wehkamp J, Herrlinger K, Stange EF. The role of defensins in the pathogenesis of inammatory bowel disease. Z Gastroenterol 2004, 42(2):333-338. [66] Wehkamp J, Harder J, Weichenthal M et al. NOD2 (CARD15) mutations in Crohns diseas are associated with diminished mucosal -defensin expression. Gut 2004, 3(11):1658-1664. [67] Wehkamp J, Schmid M, Fellermann K, Stange EF. Defensin deciency, intestinal microbes and the clinical phenotypes of Crohns disease. J Leucoc Biol 2005, 77(4):460-465. [68] Cunlie RN, Mahida YR. Expression and regulation of antimicrobial peptides in the gastrointestinal tract. J Leukoc Biol 2004, 75(1):49-58. [69] Bevins CL, Martin-Porter E, Ganz T. Defensins and innate host defence of the gastrointestinal tract. Gut 1999, 45(6):911-915.

[70] Fahlgren A, Hammarstrm S, Danielsson A, Hammarstrm ML. Increased exo o pression of antimicrobial peptides and lysozyme in colonic epithelial cells of patients with ulcerative colitis. Clin Exp Immunol 2003, 131(1):90-101. [71] Folwaczny C, Glas J, Trk HP. Crohns disease: an immunodeciency? Eur J oo Gastroenterol Hepatol 2003, 15(6):621626. [72] Wehkamp J, Salzman NH, Porter E et al. Reduced paneth cell -defensins in ileal Crohns disease. Proc Natl Acad Sci USA 2005, 102(50):18129-18134. [73] Salzman NH, Polin RA, Harris MC et al. Enteric defensin expression in necrotizing enterocolitis. Ped Res 1998, 44(1):20-26. [74] Quayle AJ, Porter EM, Nussbaum AA et al. Gene expression, immunolocalization, and secretion of human defensin-5 in human female reproductive tract. Am J Pathol 1998, 452(5):1247-1258. [75] ONeil DA, Cole SP, Martin-Porter E et al. Regulation of human beta-defensins by gastric epithelial cells in response to infection with Helicobacter pylori or stimulation with interleukin-1. Infect Immun 2000, 68(9):5412-5415. [76] Schonwetter BS, Stolzenberg ED, Zaslo MA. Epithelial antibiotics induced at sites of inammation. Science 1995, 267(5204):1645-1648. [77] Stolzenberg ED, Anderson GM, Ackermann MR, Whitlock RH, Zaslo M. Epithelial antibiotic induced in states of disease. Proc Natl Acad Sci USA 1997, 94(16):8686-8690. [78] Grupp A, Kimmel M, Fritz P et al. The expression patterns of peritoneal defensins. Perit Dial Int 2007, 27(6):654-662. [79] Frye M, Bargon J, Lembcke B, Wagner TO, Gropp R. Dierential expression of human - and -defensins mRNA in gastrointestinal epithelia. Eur J Clin Invest 2000, 30(8):695-701. [80] Wehkamp J, Harder J, Weichenthal M et al. Inducible and constitutive defensins are dierentially expressed in Crohns disease and ulcerative colitis. Inamm Bowel Dis 2003, 9(4):215223.
[81] Wehkamp J, Schwind B, Herrlinger KR et al. Innate immunity and colonic inammation: enhanced expression of epithelial -defensins. Dig Dis Sci 2002, 47(6):1349-1355. [82] Wehkamp J, Fellermann K, Herrlinger KR et al. Human -defensin 2 but not -defensin 1 is expressed preferentially in colonic mucosa of inammatory bowel disease. Eur J Gastroenterol Hepatol 2002, 14(7):745-752. [83] Fahlgren A, Hammarstrm S, Danielsson , Hammarstrm ML. -defensino A o 3 and -4 in intestinal epithelial cells display increased mRNA expression in ulcerative colitis. Clin Exp Immunol 2004, 137(2):379-385. [84] Simms LA, Doecke JD, Walsh MD, Huang N, Fowler EV, Radford-Smith GL. Reduced alpha-defensin expression is associated with inammation and not NOD2 mutation status in ileal Crohns disease. Gut 2008, 57(7):903-910. [85] Kelly P, Feakins R, Domizio P et al. Paneth cell granule depletion in the human small intestine under infective and nutritional stress. Clin Exp Immunol 2004, 135(2):303-309. [86] Wehkamp J, Wang G, Kbler I et al. The Paneth cell alpha-defensin deciency u of ileal Crohns disease is linked to Wnt/Tcf-4. J Immunol 2007, 179(5):31093118. [87] Batlle E, Henderson JT, Beghtel H et al. Beta-catenin and TCF mediate cell positioning in the intestinal epithelium by controlling the expression of EphB/ephrinB. Cell 2002, 111(2):251-263. [88] van Es JH, Jay P, Gregorie A et al. Wnt signalling induces maturation of Paneth cells in intestinal crypts. Nat Cell Biol 2005, 7(4):381-386. [89] Regueiro MD. Update in medical treatment of Crohns disease. J Clin Gastroenterol 2000, 31(4):282291. [90] Hoult JR, Moore PK. Eects of sulphasalazine and its metabolites on prostaglandin synthesis, inactivation and actions on smooth muscle. Br J Pharmacol 1980, 68(4):719730.

[91] MacDermott RP, Schloemann SR, Bertovich MJ, Nash GS, Peters M, Stenson WF. Inhibition of antibody secretion by 5-aminosalicylic acid. Gastroenterology 1989, 96(2 Pt 1):442448. [92] Stevens C, Lipman M, Fabry S et al. 5-Aminosalicylic acid abrogates T-cell proliferation by blocking interleukin-2 production in peripheral blood mononuclear cells. J Pharmacol Exp Ther 1995, 272(1):399406. [93] Bos CL, Diks SH, Hardwick JC, Walburg KV, Peppelenbosch MP, Richel DJ. Protein phosphatase 2A is required for mesalazine-dependent inhibition of Wnt/-catenin pathway activity. Carcinogenesis 2006, 27(12):2371-2382. [94] Witthft T, Pilz CS, Fellermann K, Nitschke M, Stange EF, Ludwig D. Enhano ced human beta-defensin-2 (hBD-2) expression by corticosteroids is independent of NF-B in colonic epithelial cells (CaCo2). Dig Dis Sci 2005, 50(7):1252-1259. [95] Wahl Ch, Liptay S, Adler G, Schmid RM. Sulfasalazine: a potent and specic inhibitor of nuclear factor kappa B. J Clin Invest 1998, 101(5):1163-1174. [96] Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 1995, 270(5234):286-290. [97] Brattsand R, Linden M. Cytokine modulation by glucocorticoids: mechanisms and actions in cellular studies. Aliment Pharmacol Ther 1996, 10 Suppl 2:81-90. [98] Angeli A, Masera RG, Sartori ML et al. Modulation by cytokines of glucocorticoid action. Ann NY Acad Sci 1999, 876:210220. [99] Rogler G, Meinel A, Lingauer A et al. Glucocorticoid receptors are downregulated in inamed colonic mucosa but not in peripheral blood mononuclear cells from patients with inammatory bowel disease. Eur J Clin Invest 1999, 29(4):330-336. [100] Duits LA, Rademaker M, Ravensbergen B et al. Inhibition of hBD-3, but not hBD-1 and hBD-2, mRNA expression by corticosteroids. Biochem Biophys Res Commun 2001 , 280(2):522-525.
[101] Krisanaprakornkit S, Kimball JR, Dale BA. Regulation of human beta-defensin2 in gingival epithelial cells: the involvement of mitogen-activated protein kinase pathways, but not the NF-B transcription factor family. J Immunol 2002, 168(1):316-324. [102] Duits LA, Ravensbergen B, Rademaker M, Hiemstra PS, Nibbering PH. Expression of beta-defensin 1 and 2 mRNA by human monocytes, macrophages and dendritic cells. Immunology 2002, 106(4):517-525. [103] Schlapbach C, Yawalkar N, Hunger RE. Human beta-defensin-2 and psoriasin are overexpressed in lesions of acne inversa. J Am Acad Dermatol 2009, 61(1):5865. [104] Moutsopoulos NM, Greenwell-Wild T, Wahl SM. Dierential mucosal susceptibility in HIV-1 transmission and infection. Adv Dent Res 2006, 19(1):52-56.